These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 33506481)

  • 1. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
    Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
    Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
    Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
    Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.
    Tagliaferri A; Matichecchia A; Rivolta GF; Riccardi F; Quintavalle G; Benegiamo A; Rossi R; Coppola A
    Blood Transfus; 2020 Sep; 18(5):374-385. PubMed ID: 31855153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Shah A; Solms A; Wiegmann S; Ahsman M; Berntorp E; Tiede A; Iorio A; Mancuso ME; Zhivkov T; Lissitchkov T
    Ann Hematol; 2019 Sep; 98(9):2035-2044. PubMed ID: 31236667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
    Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
    Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients.
    Bukkems LH; Heijdra JM; Mathias M; Collins PW; Hay CRM; Tait RC; Mangles S; Myers B; Evans G; Bailiff B; Curry N; Payne J; Austin S; Goedhart TMHJ; Leebeek FWG; Meijer K; Fijnvandraat K; Chowdary P; Mathôt RAA; Cnossen MH;
    Thromb Haemost; 2020 May; 120(5):747-757. PubMed ID: 32369846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects.
    Katragadda S; Neelakantan S; Diao L; Wong N
    J Clin Pharmacol; 2021 Jul; 61(7):889-900. PubMed ID: 33719084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.
    Coyle TE; Reding MT; Lin JC; Michaels LA; Shah A; Powell J
    J Thromb Haemost; 2014 Apr; 12(4):488-96. PubMed ID: 24843882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
    Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
    Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates.
    Pouplard C; Sattler L; Ryman A; Eschwege V; De Maistre E; Flaujac C; Szymezak J; Grand F; Repesse Y; Galinat H; Donnard M; Ternisien C; Iorio A; Chelle P; Jeanpierre E;
    Haemophilia; 2020 Mar; 26(2):282-289. PubMed ID: 32107819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
    Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
    Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain.
    Kim HK; Peral C; Rubio-Rodríguez D; Rubio-Terrés C
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):315-320. PubMed ID: 32597317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
    Vargas Christensen I; Loftager M; Rode F; Mørck Nielsen H; Kreilgaard M; Larsen MS
    J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.